Collecting plasma samples from patients with head and neck squamous cell carcinoma
Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck
This study is collecting blood samples from patients with head and neck cancer to see if certain markers can help predict how well treatments like cetuximab will work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Drugs / interventions | cetuximab, chemotherapy, radiation |
| Locations | 5 sites (Ottignies, Brabant Wallon and 4 other locations) |
| Trial ID | NCT02139020 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect plasma samples from patients diagnosed with squamous cell carcinoma of the head and neck at various stages: baseline, during treatment, and at progression. The collected samples will be utilized to investigate the potential of specific biomarkers in predicting the effectiveness of treatments, such as cetuximab and other targeted therapies. By analyzing these samples, researchers hope to gain insights into treatment responses and resistance mechanisms.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with squamous cell carcinoma of the head and neck who are receiving targeted therapies, including cetuximab.
Not a fit: Patients with other types of head and neck cancers or those not treated with targeted therapies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict treatment responses in patients, leading to more personalized and effective therapies.
How similar studies have performed: Other studies have shown promise in using plasma biomarkers to predict treatment responses in cancer, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients treated with radiation therapy and cetuximab according to Bonner et al * patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. * patients treated with a molecular targeted agent as a part of a clinical study Exclusion Criteria: * patients with another type of head and neck cancer * patients non treated with targeted therapies
Where this trial is running
Ottignies, Brabant Wallon and 4 other locations
- Clinique Saint-Pierre — Ottignies, Brabant Wallon, Belgium (Recruiting)
- Grand Hôpital de Charleroi — Charleroi, Hainaut, Belgium (Recruiting)
- Centre Hospitalier Jolimont-Lobbes-Nivelles-Tubize — Haine-Saint-Paul, Belgium (Recruiting)
- CHU Liège — Liège, Belgium (Recruiting)
- Clinique et Maternité Sainte-Elisabeth — Namur, Belgium (Recruiting)
Study contacts
- Principal investigator: Jean-Pascal Machiels, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Jean-Pascal Machiels, MD, PhD
- Email: jean-pascal.machiels@uclouvain.be
- Phone: 0032 2 764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.